Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency
Fragment-based lead generation has led to the discovery of a novel series of cyclic amidine-based inhibitors of β-secretase (BACE-1). Initial fragment hits with an isocytosine core having millimolar potency were identified via NMR affinity screening. Structure-guided evolution of these fragments usi...
Gespeichert in:
Veröffentlicht in: | Journal of medicinal chemistry 2007-11, Vol.50 (24), p.5912-5925 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 5925 |
---|---|
container_issue | 24 |
container_start_page | 5912 |
container_title | Journal of medicinal chemistry |
container_volume | 50 |
creator | Edwards, Philip D Albert, Jeffrey S Sylvester, Mark Aharony, David Andisik, Donald Callaghan, Owen Campbell, James B Carr, Robin A Chessari, Gianni Congreve, Miles Frederickson, Martyn Folmer, Rutger H. A Geschwindner, Stefan Koether, Gerard Kolmodin, Karin Krumrine, Jennifer Mauger, Russell C Murray, Christopher W Olsson, Lise-Lotte Patel, Sahil Spear, Nate Tian, Gaochao |
description | Fragment-based lead generation has led to the discovery of a novel series of cyclic amidine-based inhibitors of β-secretase (BACE-1). Initial fragment hits with an isocytosine core having millimolar potency were identified via NMR affinity screening. Structure-guided evolution of these fragments using X-ray crystallography together with potency determination using surface plasmon resonance and functional enzyme inhibition assays afforded micromolar inhibitors. Similarity searching around the isocytosine core led to the identification of a related series of inhibitors, the dihydroisocytosines. By leveraging the knowledge of the ligand-BACE-1 recognition features generated from the isocytosines, the dihydroisocytosines were efficiently optimized to submicromolar potency. Compound 29, with an IC50 of 80 nM, a ligand efficiency of 0.37, and cellular activity of 470 nM, emerged as the lead structure for future optimization. |
doi_str_mv | 10.1021/jm070829p |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68543259</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68543259</sourcerecordid><originalsourceid>FETCH-LOGICAL-a381t-bccb6000d32ab302e274e5ab00ef6e33840baef3c4186bde6b47e4ef2c4dc8e13</originalsourceid><addsrcrecordid>eNptkc2O0zAQxy0EYsvCgRdAvrASEgHHzod77HY_UVkqbRFHy3EmrUtiB9tZ6Gsh8Ro8E45abS-cZjTzm79m5o_Q65R8SAlNP247UhJOp_0TNElzSpKMk-wpmhBCaUILyk7QC--3hBCWUvYcnaTllOe8oBP0Z9b3rVYyaGuwbfCVk-sOTEjOpYcaL0DW-BoMuD0RLA4bwBfaK_sAbjeO3MWsfY_nOxWF8KzTtTaA__5O7kE5CFEH35qNrnSwzuOfOmzwnTS2s610eGkDGLWL49C2w1iZqaAfdIglaWp8o9cbvNDrMb9sGq30iL9EzxrZenh1iKfo69Xlan6TLL5c385ni0QynoakUqoq4tU1o7JihAItM8hlRQg0BTDGM1JJaJjKUl5UNRRVVkIGDVVZrTik7BSd7XV7Z38M4IPo4uVxU2nADl4UPM8YzacRfLcHlbPeO2hE73Qn3U6kRIweiUePIvvmIDpUHdRH8mBKBN4eAOmVbBsnjdL-yE05J6TkkUv2nPYBfj32pfsuipKVuVgt78Xq0-eL_Nv5UiyOulJ5sbWDM_F3_1nwHxEbuFA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68543259</pqid></control><display><type>article</type><title>Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency</title><source>ACS Publications</source><source>MEDLINE</source><creator>Edwards, Philip D ; Albert, Jeffrey S ; Sylvester, Mark ; Aharony, David ; Andisik, Donald ; Callaghan, Owen ; Campbell, James B ; Carr, Robin A ; Chessari, Gianni ; Congreve, Miles ; Frederickson, Martyn ; Folmer, Rutger H. A ; Geschwindner, Stefan ; Koether, Gerard ; Kolmodin, Karin ; Krumrine, Jennifer ; Mauger, Russell C ; Murray, Christopher W ; Olsson, Lise-Lotte ; Patel, Sahil ; Spear, Nate ; Tian, Gaochao</creator><creatorcontrib>Edwards, Philip D ; Albert, Jeffrey S ; Sylvester, Mark ; Aharony, David ; Andisik, Donald ; Callaghan, Owen ; Campbell, James B ; Carr, Robin A ; Chessari, Gianni ; Congreve, Miles ; Frederickson, Martyn ; Folmer, Rutger H. A ; Geschwindner, Stefan ; Koether, Gerard ; Kolmodin, Karin ; Krumrine, Jennifer ; Mauger, Russell C ; Murray, Christopher W ; Olsson, Lise-Lotte ; Patel, Sahil ; Spear, Nate ; Tian, Gaochao</creatorcontrib><description>Fragment-based lead generation has led to the discovery of a novel series of cyclic amidine-based inhibitors of β-secretase (BACE-1). Initial fragment hits with an isocytosine core having millimolar potency were identified via NMR affinity screening. Structure-guided evolution of these fragments using X-ray crystallography together with potency determination using surface plasmon resonance and functional enzyme inhibition assays afforded micromolar inhibitors. Similarity searching around the isocytosine core led to the identification of a related series of inhibitors, the dihydroisocytosines. By leveraging the knowledge of the ligand-BACE-1 recognition features generated from the isocytosines, the dihydroisocytosines were efficiently optimized to submicromolar potency. Compound 29, with an IC50 of 80 nM, a ligand efficiency of 0.37, and cellular activity of 470 nM, emerged as the lead structure for future optimization.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm070829p</identifier><identifier>PMID: 17985862</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Amidines - chemical synthesis ; Amidines - chemistry ; Amidines - pharmacology ; Amyloid Precursor Protein Secretases - antagonists & inhibitors ; Amyloid Precursor Protein Secretases - chemistry ; Amyloid Precursor Protein Secretases - genetics ; Aspartic Acid Endopeptidases - antagonists & inhibitors ; Aspartic Acid Endopeptidases - chemistry ; Aspartic Acid Endopeptidases - genetics ; Biological and medical sciences ; Cell Line ; Crystallography, X-Ray ; Cytosine - analogs & derivatives ; Cytosine - chemical synthesis ; Cytosine - chemistry ; Cytosine - pharmacology ; Fluorescence Resonance Energy Transfer ; Humans ; Ligands ; Magnetic Resonance Spectroscopy ; Medical sciences ; Models, Molecular ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Pyrimidines - chemical synthesis ; Pyrimidines - chemistry ; Pyrimidines - pharmacology ; Stereoisomerism ; Structure-Activity Relationship</subject><ispartof>Journal of medicinal chemistry, 2007-11, Vol.50 (24), p.5912-5925</ispartof><rights>Copyright © 2007 American Chemical Society</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a381t-bccb6000d32ab302e274e5ab00ef6e33840baef3c4186bde6b47e4ef2c4dc8e13</citedby><cites>FETCH-LOGICAL-a381t-bccb6000d32ab302e274e5ab00ef6e33840baef3c4186bde6b47e4ef2c4dc8e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm070829p$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm070829p$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,776,780,2752,27053,27901,27902,56713,56763</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19880078$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17985862$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Edwards, Philip D</creatorcontrib><creatorcontrib>Albert, Jeffrey S</creatorcontrib><creatorcontrib>Sylvester, Mark</creatorcontrib><creatorcontrib>Aharony, David</creatorcontrib><creatorcontrib>Andisik, Donald</creatorcontrib><creatorcontrib>Callaghan, Owen</creatorcontrib><creatorcontrib>Campbell, James B</creatorcontrib><creatorcontrib>Carr, Robin A</creatorcontrib><creatorcontrib>Chessari, Gianni</creatorcontrib><creatorcontrib>Congreve, Miles</creatorcontrib><creatorcontrib>Frederickson, Martyn</creatorcontrib><creatorcontrib>Folmer, Rutger H. A</creatorcontrib><creatorcontrib>Geschwindner, Stefan</creatorcontrib><creatorcontrib>Koether, Gerard</creatorcontrib><creatorcontrib>Kolmodin, Karin</creatorcontrib><creatorcontrib>Krumrine, Jennifer</creatorcontrib><creatorcontrib>Mauger, Russell C</creatorcontrib><creatorcontrib>Murray, Christopher W</creatorcontrib><creatorcontrib>Olsson, Lise-Lotte</creatorcontrib><creatorcontrib>Patel, Sahil</creatorcontrib><creatorcontrib>Spear, Nate</creatorcontrib><creatorcontrib>Tian, Gaochao</creatorcontrib><title>Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Fragment-based lead generation has led to the discovery of a novel series of cyclic amidine-based inhibitors of β-secretase (BACE-1). Initial fragment hits with an isocytosine core having millimolar potency were identified via NMR affinity screening. Structure-guided evolution of these fragments using X-ray crystallography together with potency determination using surface plasmon resonance and functional enzyme inhibition assays afforded micromolar inhibitors. Similarity searching around the isocytosine core led to the identification of a related series of inhibitors, the dihydroisocytosines. By leveraging the knowledge of the ligand-BACE-1 recognition features generated from the isocytosines, the dihydroisocytosines were efficiently optimized to submicromolar potency. Compound 29, with an IC50 of 80 nM, a ligand efficiency of 0.37, and cellular activity of 470 nM, emerged as the lead structure for future optimization.</description><subject>Amidines - chemical synthesis</subject><subject>Amidines - chemistry</subject><subject>Amidines - pharmacology</subject><subject>Amyloid Precursor Protein Secretases - antagonists & inhibitors</subject><subject>Amyloid Precursor Protein Secretases - chemistry</subject><subject>Amyloid Precursor Protein Secretases - genetics</subject><subject>Aspartic Acid Endopeptidases - antagonists & inhibitors</subject><subject>Aspartic Acid Endopeptidases - chemistry</subject><subject>Aspartic Acid Endopeptidases - genetics</subject><subject>Biological and medical sciences</subject><subject>Cell Line</subject><subject>Crystallography, X-Ray</subject><subject>Cytosine - analogs & derivatives</subject><subject>Cytosine - chemical synthesis</subject><subject>Cytosine - chemistry</subject><subject>Cytosine - pharmacology</subject><subject>Fluorescence Resonance Energy Transfer</subject><subject>Humans</subject><subject>Ligands</subject><subject>Magnetic Resonance Spectroscopy</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Pyrimidines - chemical synthesis</subject><subject>Pyrimidines - chemistry</subject><subject>Pyrimidines - pharmacology</subject><subject>Stereoisomerism</subject><subject>Structure-Activity Relationship</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkc2O0zAQxy0EYsvCgRdAvrASEgHHzod77HY_UVkqbRFHy3EmrUtiB9tZ6Gsh8Ro8E45abS-cZjTzm79m5o_Q65R8SAlNP247UhJOp_0TNElzSpKMk-wpmhBCaUILyk7QC--3hBCWUvYcnaTllOe8oBP0Z9b3rVYyaGuwbfCVk-sOTEjOpYcaL0DW-BoMuD0RLA4bwBfaK_sAbjeO3MWsfY_nOxWF8KzTtTaA__5O7kE5CFEH35qNrnSwzuOfOmzwnTS2s610eGkDGLWL49C2w1iZqaAfdIglaWp8o9cbvNDrMb9sGq30iL9EzxrZenh1iKfo69Xlan6TLL5c385ni0QynoakUqoq4tU1o7JihAItM8hlRQg0BTDGM1JJaJjKUl5UNRRVVkIGDVVZrTik7BSd7XV7Z38M4IPo4uVxU2nADl4UPM8YzacRfLcHlbPeO2hE73Qn3U6kRIweiUePIvvmIDpUHdRH8mBKBN4eAOmVbBsnjdL-yE05J6TkkUv2nPYBfj32pfsuipKVuVgt78Xq0-eL_Nv5UiyOulJ5sbWDM_F3_1nwHxEbuFA</recordid><startdate>20071129</startdate><enddate>20071129</enddate><creator>Edwards, Philip D</creator><creator>Albert, Jeffrey S</creator><creator>Sylvester, Mark</creator><creator>Aharony, David</creator><creator>Andisik, Donald</creator><creator>Callaghan, Owen</creator><creator>Campbell, James B</creator><creator>Carr, Robin A</creator><creator>Chessari, Gianni</creator><creator>Congreve, Miles</creator><creator>Frederickson, Martyn</creator><creator>Folmer, Rutger H. A</creator><creator>Geschwindner, Stefan</creator><creator>Koether, Gerard</creator><creator>Kolmodin, Karin</creator><creator>Krumrine, Jennifer</creator><creator>Mauger, Russell C</creator><creator>Murray, Christopher W</creator><creator>Olsson, Lise-Lotte</creator><creator>Patel, Sahil</creator><creator>Spear, Nate</creator><creator>Tian, Gaochao</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20071129</creationdate><title>Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency</title><author>Edwards, Philip D ; Albert, Jeffrey S ; Sylvester, Mark ; Aharony, David ; Andisik, Donald ; Callaghan, Owen ; Campbell, James B ; Carr, Robin A ; Chessari, Gianni ; Congreve, Miles ; Frederickson, Martyn ; Folmer, Rutger H. A ; Geschwindner, Stefan ; Koether, Gerard ; Kolmodin, Karin ; Krumrine, Jennifer ; Mauger, Russell C ; Murray, Christopher W ; Olsson, Lise-Lotte ; Patel, Sahil ; Spear, Nate ; Tian, Gaochao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a381t-bccb6000d32ab302e274e5ab00ef6e33840baef3c4186bde6b47e4ef2c4dc8e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Amidines - chemical synthesis</topic><topic>Amidines - chemistry</topic><topic>Amidines - pharmacology</topic><topic>Amyloid Precursor Protein Secretases - antagonists & inhibitors</topic><topic>Amyloid Precursor Protein Secretases - chemistry</topic><topic>Amyloid Precursor Protein Secretases - genetics</topic><topic>Aspartic Acid Endopeptidases - antagonists & inhibitors</topic><topic>Aspartic Acid Endopeptidases - chemistry</topic><topic>Aspartic Acid Endopeptidases - genetics</topic><topic>Biological and medical sciences</topic><topic>Cell Line</topic><topic>Crystallography, X-Ray</topic><topic>Cytosine - analogs & derivatives</topic><topic>Cytosine - chemical synthesis</topic><topic>Cytosine - chemistry</topic><topic>Cytosine - pharmacology</topic><topic>Fluorescence Resonance Energy Transfer</topic><topic>Humans</topic><topic>Ligands</topic><topic>Magnetic Resonance Spectroscopy</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Pyrimidines - chemical synthesis</topic><topic>Pyrimidines - chemistry</topic><topic>Pyrimidines - pharmacology</topic><topic>Stereoisomerism</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Edwards, Philip D</creatorcontrib><creatorcontrib>Albert, Jeffrey S</creatorcontrib><creatorcontrib>Sylvester, Mark</creatorcontrib><creatorcontrib>Aharony, David</creatorcontrib><creatorcontrib>Andisik, Donald</creatorcontrib><creatorcontrib>Callaghan, Owen</creatorcontrib><creatorcontrib>Campbell, James B</creatorcontrib><creatorcontrib>Carr, Robin A</creatorcontrib><creatorcontrib>Chessari, Gianni</creatorcontrib><creatorcontrib>Congreve, Miles</creatorcontrib><creatorcontrib>Frederickson, Martyn</creatorcontrib><creatorcontrib>Folmer, Rutger H. A</creatorcontrib><creatorcontrib>Geschwindner, Stefan</creatorcontrib><creatorcontrib>Koether, Gerard</creatorcontrib><creatorcontrib>Kolmodin, Karin</creatorcontrib><creatorcontrib>Krumrine, Jennifer</creatorcontrib><creatorcontrib>Mauger, Russell C</creatorcontrib><creatorcontrib>Murray, Christopher W</creatorcontrib><creatorcontrib>Olsson, Lise-Lotte</creatorcontrib><creatorcontrib>Patel, Sahil</creatorcontrib><creatorcontrib>Spear, Nate</creatorcontrib><creatorcontrib>Tian, Gaochao</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Edwards, Philip D</au><au>Albert, Jeffrey S</au><au>Sylvester, Mark</au><au>Aharony, David</au><au>Andisik, Donald</au><au>Callaghan, Owen</au><au>Campbell, James B</au><au>Carr, Robin A</au><au>Chessari, Gianni</au><au>Congreve, Miles</au><au>Frederickson, Martyn</au><au>Folmer, Rutger H. A</au><au>Geschwindner, Stefan</au><au>Koether, Gerard</au><au>Kolmodin, Karin</au><au>Krumrine, Jennifer</au><au>Mauger, Russell C</au><au>Murray, Christopher W</au><au>Olsson, Lise-Lotte</au><au>Patel, Sahil</au><au>Spear, Nate</au><au>Tian, Gaochao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2007-11-29</date><risdate>2007</risdate><volume>50</volume><issue>24</issue><spage>5912</spage><epage>5925</epage><pages>5912-5925</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>Fragment-based lead generation has led to the discovery of a novel series of cyclic amidine-based inhibitors of β-secretase (BACE-1). Initial fragment hits with an isocytosine core having millimolar potency were identified via NMR affinity screening. Structure-guided evolution of these fragments using X-ray crystallography together with potency determination using surface plasmon resonance and functional enzyme inhibition assays afforded micromolar inhibitors. Similarity searching around the isocytosine core led to the identification of a related series of inhibitors, the dihydroisocytosines. By leveraging the knowledge of the ligand-BACE-1 recognition features generated from the isocytosines, the dihydroisocytosines were efficiently optimized to submicromolar potency. Compound 29, with an IC50 of 80 nM, a ligand efficiency of 0.37, and cellular activity of 470 nM, emerged as the lead structure for future optimization.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>17985862</pmid><doi>10.1021/jm070829p</doi><tpages>14</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 2007-11, Vol.50 (24), p.5912-5925 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_68543259 |
source | ACS Publications; MEDLINE |
subjects | Amidines - chemical synthesis Amidines - chemistry Amidines - pharmacology Amyloid Precursor Protein Secretases - antagonists & inhibitors Amyloid Precursor Protein Secretases - chemistry Amyloid Precursor Protein Secretases - genetics Aspartic Acid Endopeptidases - antagonists & inhibitors Aspartic Acid Endopeptidases - chemistry Aspartic Acid Endopeptidases - genetics Biological and medical sciences Cell Line Crystallography, X-Ray Cytosine - analogs & derivatives Cytosine - chemical synthesis Cytosine - chemistry Cytosine - pharmacology Fluorescence Resonance Energy Transfer Humans Ligands Magnetic Resonance Spectroscopy Medical sciences Models, Molecular Neuropharmacology Pharmacology. Drug treatments Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychopharmacology Pyrimidines - chemical synthesis Pyrimidines - chemistry Pyrimidines - pharmacology Stereoisomerism Structure-Activity Relationship |
title | Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T04%3A52%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Application%20of%20Fragment-Based%20Lead%20Generation%20to%20the%20Discovery%20of%20Novel,%20Cyclic%20Amidine%20%CE%B2-Secretase%20Inhibitors%20with%20Nanomolar%20Potency,%20Cellular%20Activity,%20and%20High%20Ligand%20Efficiency&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Edwards,%20Philip%20D&rft.date=2007-11-29&rft.volume=50&rft.issue=24&rft.spage=5912&rft.epage=5925&rft.pages=5912-5925&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm070829p&rft_dat=%3Cproquest_cross%3E68543259%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68543259&rft_id=info:pmid/17985862&rfr_iscdi=true |